We therefore propose that ITGA5 provides breast cancer cells (and DTCs) with a survival advantage by binding to fibronectin in the bone marrow, which explains, at least in part, why high ITGA5 expression levels in primary tumors predict the occurrence of future bone metastases in patients with early stage breast cancer. The gene discussed is ITGA5; the disease is breast carcinoma.